Overview
My long-term goal is to develop new therapies to treat patients with gastrointestinal and other solid tumors. To accomplish this, I am active in designing, writing, and running phase I and II clinical trials. I am also interested in the correlative science that furthers our understanding of cancer at a molecular level. I am interested in the identification of biomarkers, which are characteristics of a given patient's tumor that may help us to understand his or her prognosis or how well he or she may respond to a given therapy. The overall objective of this research is to use the knowledge gained to personalize care and find the very best therapies that will enable our patients to fight their cancer.
Current Appointments & Affiliations
Associate Professor of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2017 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results.
Journal Article Clin Cancer Res · April 15, 2026 PURPOSE: The utility of combination treatment with gemcitabine and camonsertib, an ataxia telangiectasia and Rad3-related kinase inhibitor, in mediating tumor cell death was assessed in preclinical models, prompting clinical investigation. The phase Ib TRE ... Full text Link to item CiteSafety and feasibility of talimogene laherparepvec in peritoneal surface malignancies: Results from the TEMPO trial.
Journal Article Mol Ther Oncol · March 19, 2026 Peritoneal surface malignancies (PSMs) remain a therapeutic challenge, particularly in patients with unresectable disease who cannot benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. The Talimogene Laherparepvec for the Trea ... Full text Link to item CiteOpen-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies.
Journal Article ESMO Open · July 2024 BACKGROUND: Pemigatinib is an oral, potent, selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor. FIGHT-101, a three-part, open-label, first-in-human, phase I/II study (NCT02393248), evaluated pemigatinib in patients with advanced solid tumors. ... Full text Link to item CiteRecent Grants
RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenoca
Clinical TrialPrincipal Investigator · Awarded by Revolution Medicines, Inc · 2026 - 2031Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors (BiPAVE-001)
Clinical TrialPrincipal Investigator · Awarded by OncoC4, Inc. · 2026 - 2031A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in participants with advanced solid tumors.
Clinical TrialPrincipal Investigator · Awarded by BioNTech SE · 2025 - 2030View All Grants
Education
Duke University, School of Medicine ·
2008
M.D.
Duke University ·
2007
Ph.D.